Equities

Alkermes Plc

Alkermes Plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.18
  • Today's Change0.48 / 1.73%
  • Shares traded126.01k
  • 1 Year change+15.59%
  • Beta0.4363
Data delayed at least 15 minutes, as of Nov 22 2024 15:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments773608536
Total Receivables, Net333297327
Total Inventory186181150
Prepaid expenses984449
Other current assets, total94----
Total current assets1,4861,1301,062
Property, plant & equipment, net318441457
Goodwill, net839393
Intangibles, net1.993874
Long term investments40140236
Note receivable - long term------
Other long term assets126.7921
Total assets2,1361,9642,024
LIABILITIES
Accounts payable663356
Accrued expenses444455406
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.003.003.00
Other current liabilities, total7.276.826.34
Total current liabilities520498471
Total long term debt288290293
Total debt291293296
Deferred income tax------
Minority interest------
Other liabilities, total126132148
Total liabilities934920912
SHAREHOLDERS EQUITY
Common stock1.731.691.66
Additional paid-in capital2,7372,9132,798
Retained earnings (accumulated deficit)(1344)(1699)(1541)
Treasury stock - common(189)(161)(143)
Unrealized gain (loss)------
Other equity, total(3.11)(11)(3.72)
Total equity1,2031,0441,113
Total liabilities & shareholders' equity2,1361,9642,024
Total common shares outstanding167164162
Treasury shares - common primary issue5.594.573.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.